Literature DB >> 7045417

Epithelial ovarian cancer and combination oral contraceptives.

L Rosenberg, S Shapiro, D Slone, D W Kaufman, S P Helmrich, O S Miettinen, P D Stolley, N B Rosenshein, D Schottenfeld, R L Engle.   

Abstract

The risk of epithelial ovarian cancer in relation to the use of combination oral contraceptives was evaluated in a case-control study of women younger than 60 years. Combination oral contraceptives were used by 35 (26%) of 136 cases and 187 (35%) of 539 controls. The relative risk estimate for combination oral contraceptive use was 0.6 (95% confidence interval, 0.4 to 0.9). The reduction in risk appeared to persist for as long as ten years after use had ceased and to be greater for longer durations of use, but these results were not statistically significant. The findings were not explained by parity or by other identified potential confounding factors. The results suggest that the use of combination oral contraceptives protects against epithelial ovarian cancer.

Entities:  

Keywords:  Age Factors; Americas; Canada; Cancer; Contraception; Contraceptive Methods; Control Groups; Developed Countries; Diseases; Family Planning; Neoplasms; North America; Northern America; Oral Contraceptives; Oral Contraceptives, Combined; Ovarian Cancer; Research Methodology; United States

Mesh:

Substances:

Year:  1982        PMID: 7045417

Source DB:  PubMed          Journal:  JAMA        ISSN: 0098-7484            Impact factor:   56.272


  11 in total

Review 1.  Exogenous hormones in the aetiology of cancer in women.

Authors:  M P Vessey
Journal:  J R Soc Med       Date:  1984-07       Impact factor: 5.344

2.  How to induce ovarian cancer: and how not to.

Authors:  J S Scott
Journal:  Br Med J (Clin Res Ed)       Date:  1984-09-29

Review 3.  Oral contraceptives and cancer: an update.

Authors:  C La Vecchia; A Altieri; S Franceschi; A Tavani
Journal:  Drug Saf       Date:  2001       Impact factor: 5.606

4.  A case-control study of oral contraceptive use and incident breast cancer.

Authors:  Lynn Rosenberg; Yuqing Zhang; Patricia F Coogan; Brian L Strom; Julie R Palmer
Journal:  Am J Epidemiol       Date:  2008-12-13       Impact factor: 4.897

5.  Family history in ovarian cancer referral population.

Authors:  L A Berg; S Robert Young; K A Brooks; A M Davis; S Terry Smith
Journal:  J Genet Couns       Date:  1996-03       Impact factor: 2.537

Review 6.  The relationship between oral contraceptive use, cancer and vascular disease.

Authors:  C La Vecchia; S Franceschi; P Bruzzi; F Parazzini; P Boyle
Journal:  Drug Saf       Date:  1990 Nov-Dec       Impact factor: 5.606

7.  Investigation of mammographic breast density as a risk factor for ovarian cancer.

Authors:  Karen J Wernli; Ellen S O'Meara; Karla Kerlikowske; Diana L Miglioretti; Carolyn Y Muller; Tracy Onega; Brian L Sprague; Louise M Henderson; Diana S M Buist
Journal:  J Natl Cancer Inst       Date:  2013-12-05       Impact factor: 13.506

8.  Hypotheses: melatonin/steroid combination contraceptives will prevent breast cancer.

Authors:  M Cohen; R A Small; A Brzezinski
Journal:  Breast Cancer Res Treat       Date:  1995-03       Impact factor: 4.872

9.  Oral contraceptive use and the risk of epithelial ovarian cancer.

Authors:  C La Vecchia; S Franceschi; A Decarli
Journal:  Br J Cancer       Date:  1984-07       Impact factor: 7.640

10.  Norgestrel and gestodene stimulate breast cancer cell growth through an oestrogen receptor mediated mechanism.

Authors:  W H Catherino; M H Jeng; V C Jordan
Journal:  Br J Cancer       Date:  1993-05       Impact factor: 7.640

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.